Please ensure Javascript is enabled for purposes of website accessibility

Reliant Pharma Files 300 Million IPO

Maker of heart drugs says a majority of the shares to be sold will be newly issued and a portion will be sold by a stockholder.Reliant Pharmaceuticals, a Liberty Corner maker of heart drugs, plans to raise up to $300 million in an initial public offering.

In a Form S-1 filed with the U.S. Securities and Exchange Commission Friday, Reliant said a majority of the shares to be sold will be newly issued and a portion will be sold by a stockholder.

Reliant will not receive any of the proceeds from the sale of shares by the selling stockholder.

Goldman, Sachs is the lead manager and sole book-runner for the offering.

Reliant plans to trade on the New York Stock Exchange under the ticker symbol “RR.”

NJBIZ Business Events

2022 NJBIZ Panel Discussion: Cybersecurity

Tuesday, February 22, 2022
2022 NJBIZ Panel Discussion: Cybersecurity

NJBIZ Digi-Tech Innovator Awards 2022

Thursday, March 31, 2022
NJBIZ Digi-Tech Innovator Awards 2022

NJBIZ Leaders in Finance 2022

Wednesday, April 27, 2022
NJBIZ Leaders in Finance 2022

NJBIZ Leaders in Law 2022

Wednesday, May 25, 2022
NJBIZ Leaders in Law 2022